Jupiter Asset Management Ltd. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Jupiter Asset Administration Ltd. lowered its holdings in shares of Regeneron Prescribed drugs, Inc. (NASDAQ:REGN – Free Report) by 25.0% within the 2nd quarter, based on its most up-to-date 13F submitting with the Securities and Alternate Fee. The institutional investor owned 19,964 shares of the biopharmaceutical firm’s inventory after promoting 6,654 shares throughout the quarter. Jupiter Asset Administration Ltd.’s holdings in Regeneron Prescribed drugs had been value $14,345,000 as of its most up-to-date submitting with the Securities and Alternate Fee.

A number of different hedge funds have additionally just lately added to or lowered their stakes within the enterprise. NewSquare Capital LLC boosted its stake in shares of Regeneron Prescribed drugs by 1,450.0% throughout the 1st quarter. NewSquare Capital LLC now owns 31 shares of the biopharmaceutical firm’s inventory value $25,000 after buying a further 29 shares over the past quarter. Sunbelt Securities Inc. acquired a brand new stake in shares of Regeneron Prescribed drugs throughout the 1st quarter value about $25,000. Manchester Capital Administration LLC boosted its stake in shares of Regeneron Prescribed drugs by 740.0% throughout the 1st quarter. Manchester Capital Administration LLC now owns 42 shares of the biopharmaceutical firm’s inventory value $35,000 after buying a further 37 shares over the past quarter. BerganKDV Wealth Administration LLC boosted its stake in shares of Regeneron Prescribed drugs by 444.4% throughout the 2nd quarter. BerganKDV Wealth Administration LLC now owns 49 shares of the biopharmaceutical firm’s inventory value $35,000 after buying a further 40 shares over the past quarter. Lastly, Activest Wealth Administration acquired a brand new stake in shares of Regeneron Prescribed drugs throughout the 2nd quarter value about $40,000. 84.15% of the inventory is presently owned by hedge funds and different institutional buyers.

Wall Road Analyst Weigh In

A number of equities analysis analysts just lately issued experiences on the inventory. Barclays raised their goal value on shares of Regeneron Prescribed drugs from $900.00 to $925.00 and gave the inventory an “obese” ranking in a analysis report on Monday, August twenty first. Canaccord Genuity Group raised shares of Regeneron Prescribed drugs from a “maintain” ranking to a “purchase” ranking and raised their goal value for the inventory from $720.00 to $992.00 in a analysis report on Monday, August twenty first. Canaccord Genuity Group raised shares of Regeneron Prescribed drugs from a “maintain” ranking to a “purchase” ranking and raised their goal value for the inventory from $720.00 to $992.00 in a analysis report on Monday, August twenty first. Westpark Capital began protection on shares of Regeneron Prescribed drugs in a analysis report on Friday, September fifteenth. They issued a “maintain” ranking on the inventory. Lastly, Argus raised their value goal on shares of Regeneron Prescribed drugs from $825.00 to $920.00 and gave the corporate a “purchase” ranking in a report on Friday, September fifteenth. One analyst has rated the inventory with a promote ranking, six have issued a maintain ranking and twenty have issued a purchase ranking to the corporate’s inventory. In keeping with MarketBeat.com, the inventory presently has a median ranking of “Average Purchase” and a consensus goal value of $903.64.

Examine Out Our Newest Analysis Report on REGN

Insiders Place Their Bets

In different Regeneron Prescribed drugs information, Director Christine A. Poon offered 12,280 shares of Regeneron Prescribed drugs inventory in a transaction dated Wednesday, August twenty third. The inventory was offered at a median value of $839.97, for a complete transaction of $10,314,831.60. Following the transaction, the director now owns 2,037 shares of the corporate’s inventory, valued at roughly $1,711,018.89. The transaction was disclosed in a doc filed with the SEC, which is out there at this hyperlink. In different Regeneron Prescribed drugs information, Director Christine A. Poon offered 12,280 shares of Regeneron Prescribed drugs inventory in a transaction dated Wednesday, August twenty third. The inventory was offered at a median value of $839.97, for a complete transaction of $10,314,831.60. Following the transaction, the director now owns 2,037 shares of the corporate’s inventory, valued at roughly $1,711,018.89. The transaction was disclosed in a doc filed with the SEC, which is out there at this hyperlink. Additionally, Director Bonnie L. Bassler offered 853 shares of Regeneron Prescribed drugs inventory in a transaction dated Monday, August twenty first. The shares had been offered at a median value of $829.00, for a complete worth of $707,137.00. Following the transaction, the director now straight owns 1,247 shares within the firm, valued at roughly $1,033,763. The disclosure for this sale will be discovered right here. Within the final quarter, insiders have offered 34,356 shares of firm inventory value $28,811,415. Firm insiders personal 8.83% of the corporate’s inventory.

Regeneron Prescribed drugs Inventory Efficiency

Shares of REGN opened at $802.43 on Friday. The agency has a fifty day transferring common of $817.51 and a 200-day transferring common of $781.77. The corporate has a debt-to-equity ratio of 0.11, a fast ratio of 4.47 and a present ratio of 5.18. The corporate has a market cap of $87.42 billion, a price-to-earnings ratio of twenty-two.89, a price-to-earnings-growth ratio of three.00 and a beta of 0.13. Regeneron Prescribed drugs, Inc. has a 1 12 months low of $668.00 and a 1 12 months excessive of $853.97.

Regeneron Prescribed drugs (NASDAQ:REGN – Get Free Report) final posted its quarterly earnings knowledge on Thursday, November 2nd. The biopharmaceutical firm reported $11.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.58 by $2.01. The agency had income of $3.36 billion for the quarter, in comparison with the consensus estimate of $3.23 billion. Regeneron Prescribed drugs had a return on fairness of 18.61% and a web margin of 30.47%. The enterprise’s income for the quarter was up 14.5% in comparison with the identical quarter final 12 months. Throughout the identical quarter within the earlier 12 months, the corporate earned $9.98 EPS. As a bunch, equities analysts anticipate that Regeneron Prescribed drugs, Inc. will submit 35.55 earnings per share for the present 12 months.

Regeneron Prescribed drugs Firm Profile

(Free Report)

Regeneron Prescribed drugs, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating numerous ailments worldwide. The corporate’s merchandise embody EYLEA injection to deal with neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Wish to see what different hedge funds are holding REGN? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Regeneron Prescribed drugs, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

This instantaneous information alert was generated by narrative science know-how and monetary knowledge from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Regeneron Prescribed drugs, you will wish to hear this.

MarketBeat retains observe of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Regeneron Prescribed drugs wasn’t on the record.

Whereas Regeneron Prescribed drugs presently has a “Average Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The 5 Shares Right here

Elon Musk's Next Move Cover

Questioning whenever you’ll lastly be capable to spend money on SpaceX, StarLink or The Boring Firm? Click on the hyperlink beneath to study when Elon Musk will let these firms lastly IPO.

Get This Free Report

admin

Leave a Reply

Your email address will not be published. Required fields are marked *